2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4077 Duffy-null genotype is associated with response depth but not survival or transplant -associated outcomes in multiple myeloma

Ayo Samuel Falade, MD, MBA, Hongwei Tang, PhD2, Michael Howe3, Mahek Bai, MS4, Suganti Shivaram, MBBS5, Stacey J. Lehman6, Huihuang Yan, PhD7, Yan Asmann, PhD8, Rahma Warsame, MD9, Megan Weivoda, PhD10, Christen M Dillard, MD11, Krina Patel Jr, MD, MSc12, Olisaemeka Ogbue, MBBS13, Richard C. Godby, MD14, Ronald Go, MD15, Sikander Ailawadhi, MD16, Shaji Kumar, MD17, S. Vincent Rajkumar, MD18, Michelle A.T. Hildebrandt, PhD19, Linda Baughn, PhD20, Joselle M Cook, M.D.21
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Jacksonville, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Jacksonville, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 MD Anderson Cancer Center, Houston, Texas, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States

Background: Patients of African genetic similarity have a two- to three-fold higher incidence of multiple myeloma (MM) and historically worse outcomes, largely attributed to unequal access to effective therapy; with equal access, survival is comparable or superior to that of patients of European genetic similarity. The Duffy-null genotype (rs2814778-CC in the ACKR1/DARC promoter), present in ~70-75% of individuals of African ancestry, is associated with a lower baseline absolute neutrophil count but not increased infection risk. A recent DETERMINATION subgroup analysis suggested that Duffy status may modify the progression free survival (PFS) effect of upfront ASCT, raising the question of whether Duffy-null status independently affects treatment response, survival, or autologous stem-cell transplantation- (ASCT) associated outcomes in MM. We addressed this in a genetically characterized discovery cohort with independent validation.

Methods: The discovery cohort (Mayo Clinic) comprised 279 newly diagnosed MM patients (1993-2018). Genetic ancestry/similarity was inferred by Markov Chain Monte Carlo (MCMC) built into Admixture (version- 1.3.0) using 1000 Genomes reference populations (and grouped as African 115, European 137, Asian 22, other/admixed 5); Duffy status was defined by rs2814778 (CC=null; TT/TC=positive); median follow-up was 94 months. Validation used an independent MD Anderson cohort (n=773; 31% African-predominant genetic similarity, 22.4% Duffy-null; median follow-up 7.6 years). Depth-of-response endpoints (≥VGPR and CR/sCR, IMWG criteria) were modeled by logistic regression and PFS/overall survival (OS) by Cox regression across the three major genetic similarity groups (reference=African). Because ASCT timing introduces immortal-time bias, ASCT was modeled as a time-dependent covariate, with effect modification tested by likelihood-ratio test.

Results: In the discovery cohort, the Duffy-null genotype (92/279, 33%; 91/92 within African genetic similarity) was associated with lower odds of achieving ≥VGPR (unadjusted OR 0.58, 95% CI 0.34-0.97, p=0.037; adjusted for age, treatment era, and ASCT: OR 0.37, 0.20-0.67, p=0.001), whereas ASCT was the strongest predictor of ≥VGPR (adjusted OR 4.04, 2.14-7.86, p<0.001). Genetic similarity was not associated with ≥VGPR (p=0.93) or CR/sCR (p=0.90). Median PFS was 36 months and median OS 82 months; neither genetic similarity nor Duffy-null status was associated with PFS or OS (Duffy-null PFS HR 1.06, 0.77-1.45, p=0.73; OS HR 0.98, 0.69-1.40, p=0.93). In time-dependent models, ASCT was not associated with improved PFS (HR 1.17, p=0.33) or OS (HR 1.25, p=0.21), with no effect modification by genetic similarity or Duffy status. No ASCT-by-Duffy interaction was observed for PFS or OS (p-interaction= 0.56 and 0.74), nor was ASCT-by-genetic-similarity interaction observed (p-interaction=0.92 and 0.68). These findings were confirmed in the independent MD Anderson validation cohort; genetic similarity was not associated with PFS or OS (European vs African PFS HR 1.00, [95% CI 0.80-1.25], p=0.99; OS HR 1.17, [95% CI 0.94-1.46], p=0.17), and the Duffy-null genotype was not associated with shorter PFS (HR 1.19, [95% CI 0.88-1.35], p=0.44), with the OS estimate trending favorably (HR 0.81, [95% CI 0.64-1.03], p=0.080).Duffy-null status and African genetic similarity were ~99% collinear, limiting attribution to either alone.

Conclusions: In two genetically characterized cohorts spanning multiple treatment eras, Duffy-null status was associated with lower odds of ≥VGPR in the discovery cohort but was not associated with PFS or OS, and no evidence of ASCT-by-Duffy or ASCT-by-genetic-similarity effect modification was observed. These findings support the hypothesis that Duffy-null status may influence count-based treatment delivery more than adverse myeloma biology, warranting genotype-aware interpretation of neutropenia in MM trials and practice. Because Duffy-null status and African genetic similarity were nearly collinear, genotype- and ancestry-specific effects cannot be fully separated. These data do not support modifying or withholding ASCT based on Duffy status.

Ayo Samuel Falade, MD, MBA: No relevant conflicts of interest to declare.